<abstract xmlns="http://www.w3.org/1999/xhtml"><bold>Background</bold>. We aimed to determine the relationship between endocan and cirrhotic cardiomyopathy.<bold>Materials and methods</bold>. Patients with liver cirrhosis and no heart disease were included in a prospective observational study with liver disease decompensation and death as primary outcomes.<bold>Results</bold>. 83 cirrhotic patients were included and 32 had cirrhotic cardiomyopathy. Endocan levels were significantly lower in patients with cirrhotic cardiomyopathy (5.6 <italic>vs</italic>. 7 ng/mL, p = 0.034). Endocan correlated with severity of cirrhosis, time to decompensation or death from liver disease (OR 4.5 95% CI 1.06-31.1).<bold>Conclusion</bold>. Endocan is a promising biomarker of severity of cirrhosis and may help in the diagnosis of cardiac dysfunction in this population.</abstract>

Background. We aimed to determine the relationship between endocan and cirrhotic cardiomyopathy.Materials and methods. Patients with liver cirrhosis and no heart disease were included in a prospective observational study with liver disease decompensation and death as primary outcomes.Results. 83 cirrhotic patients were included and 32 had cirrhotic cardiomyopathy. Endocan levels were significantly lower in patients with cirrhotic cardiomyopathy (5.6 vs. 7 ng/mL, p = 0.034). Endocan correlated with severity of cirrhosis, time to decompensation or death from liver disease (OR 4.5 95% CI 1.06-31.1).Conclusion. Endocan is a promising biomarker of severity of cirrhosis and may help in the diagnosis of cardiac dysfunction in this population.

The diagnostic and prognostic value of serum endocan in patients with cirrhotic cardiomyopathy

Gastroenterology Department, “Colentina” Clinical Hospital

Cardiology Department, “Colentina” Clinical Hospital

Internal Medicine Department, “Colentina” Clinical Hospital

Romanian Journal of Internal Medicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Background. We aimed to determine the relationship between endocan and cirrhotic cardiomyopathy.Materials and methods. Patients with liver cirrhosis and no...

The diagnostic and prognostic value of serum endocan in patients with cirrhotic cardiomyopathy

Online veröffentlicht: 29. Aug. 2018

Seitenbereich: 182 - 192

Eingereicht: 08. Feb. 2018

DOI: https://doi.org/10.2478/rjim-2018-0007

Schlüsselwörter
cirrhotic cardiomyopathy, endocan, echocardiography, follow-up studies, portal hypertension, haemodynamics, cirrhosis

© 2018 Andrei Mihai Voiosu et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

The diagnostic and prognostic value of serum endocan in patients with cirrhotic cardiomyopathy

Online veröffentlicht: 29. Aug. 2018

Seitenbereich: 182 - 192

Eingereicht: 08. Feb. 2018

DOI: https://doi.org/10.2478/rjim-2018-0007

Schlüsselwörtercirrhotic cardiomyopathy, endocan, echocardiography, follow-up studies, portal hypertension, haemodynamics, cirrhosis

© 2018 Andrei Mihai Voiosu et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Schlüsselwörter
cirrhotic cardiomyopathy, endocan, echocardiography, follow-up studies, portal hypertension, haemodynamics, cirrhosis